FM
VRTX icon

Family Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Family Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-9,758
Closed -$1.77M – 194
2021
Q3 		$1.77M Sell
9,758
-23
-0.2% -$4.49K 0.49% 54
2021
Q2 		$1.97M Sell
9,781
-569
-5% -$119K 0.52% 50
2021
Q1 		$2.22M Buy
+10,350
New +$2.27M 0.7% 43

Other funds holding VRTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Family Management's VRTX Position: Q4 2021 in Review

Family Management sold out of Vertex Pharmaceuticals (VRTX) in Q4 2021, closing a stake of 9,758 shares — an estimated $1.77M sold.

Family Management first reported a position in VRTX in Q1 2021 and held it in 3 quarters. The position peaked at $2.22M in Q1 2021. 1,034 funds tracked by Wall St. Rank hold VRTX as of Q4 2021.

  • Family Management reported no remaining Vertex Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Family Management sold 9,758 Vertex Pharmaceuticals shares in Q4 2021, an estimated $1.77M.
  • Family Management first reported a position in Vertex Pharmaceuticals in Q1 2021 and held it in 3 quarters.
  • Family Management's Vertex Pharmaceuticals position peaked at $2.22M in Q1 2021.
  • 1,034 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2021.

Based on Family Management's 13F filing for Q4 2021, filed 14 Feb 2022.